BioCentury | Mar 9, 2020
Deals

Lonza ‘cocoons’ give academics route to scale autologous cell therapies

A deal granting academics access to Lonza’s automated manufacturing pods could ramp up patient access to next-generation autologous cell therapies. In the long term, widespread adoption of such decentralized patient-scale technologies could help redefine modalities...
BioCentury | Feb 21, 2020
Product Development

T regs are back - promising to do for autoimmunity what CAR Ts have done in cancer

Drug developers are giving regulatory T cells a second look as treatments for autoimmune disease. The difference this time is that they can leverage orthogonal benefits from CAR T cells in cancer, capitalizing on new...
BioCentury | Feb 7, 2020
Emerging Company Profile

Led by Bluestone, Sonoma launches to turn Tregs against autoimmunity

Founded by a team of T cell biology pioneers including the Parker Institute’s Jeffrey Bluestone, Sonoma Biotherapeutics launched Thursday with a $40 million series A round to develop Treg-based cell therapies for autoimmune and neurodegenerative...
BioCentury | Dec 27, 2019
Product Development

Two-year-old Xyphos gains exit as Astellas scoops up CAR T switch platform

After splitting from parent company AvidBiotics in 2017, Xyphos has taken a short path to reward the decision with a takeout by Astellas. The Japanese pharma will use the technology to build its immuno-oncology pipeline,...
BC Innovations | Dec 6, 2019
Targets & Mechanisms

Emerging immuno-oncology mechanisms at ASH 2019

Researchers are finding new ways to monitor the immune system in hematologic diseases that could have implications for optimizing immuno-oncology therapies, according to BioCentury’s analysis of emerging targets at ASH 2019. In abstracts released ahead...
BC Innovations | Nov 1, 2019
Tools & Techniques

Draper’s devices take on cell therapy’s pain points

Having surveyed more than 60 cell therapy developers on what keeps them up at night, The Charles Stark Draper Laboratory Inc. is building a suite of microfluidic and acoustic tools to overcome the inefficiencies that...
BioCentury | Nov 1, 2019
Emerging Company Profile

Tmunity: Manufacturing momentum for CAR and TCR therapies

Tmunity’s $75 million series B round will enable the company to keep advancing its CMC capabilities alongside its clinical and preclinical engineered CAR and TCR therapies for solid and blood tumors. Andreessen Horowitz (a16z) led...
BioCentury | Oct 17, 2019
Emerging Company Profile

Parker Institute’s ArsenalBio launches with $85M to build cell engineering war chest

ArsenalBio launched Thursday with $85 million in a series A round to combine the technologies of its six Parker Institute co-founders into a suite of tools the company thinks could overcome key hurdles to cell...
BC Extra | Sep 19, 2019
Preclinical News

Sept. 19 Preclinical Quick Takes: Celsius' single-cell analysis; plus Merck's RSV therapy, glial cell transplant and methylation profiles for tumors

Celsius gets three single-cell analysis partners  Through separate deals, Celsius Therapeutics Inc. partnered with the Parker Institute for Cancer Immunotherapy, Institut Gustave-Roussy and University Health Network to apply its single-cell genomics platform, which includes machine-learning...
BC Innovations | May 30, 2019
Product Development

CAR T developers plan steps to reach more indications

As CAR T developers take stock after the first wave of approvals, they are drawing a to-do list of what changes are needed to broaden the modality from its narrow indications and fully exploit its...
Items per page:
1 - 10 of 49
BioCentury | Mar 9, 2020
Deals

Lonza ‘cocoons’ give academics route to scale autologous cell therapies

A deal granting academics access to Lonza’s automated manufacturing pods could ramp up patient access to next-generation autologous cell therapies. In the long term, widespread adoption of such decentralized patient-scale technologies could help redefine modalities...
BioCentury | Feb 21, 2020
Product Development

T regs are back - promising to do for autoimmunity what CAR Ts have done in cancer

Drug developers are giving regulatory T cells a second look as treatments for autoimmune disease. The difference this time is that they can leverage orthogonal benefits from CAR T cells in cancer, capitalizing on new...
BioCentury | Feb 7, 2020
Emerging Company Profile

Led by Bluestone, Sonoma launches to turn Tregs against autoimmunity

Founded by a team of T cell biology pioneers including the Parker Institute’s Jeffrey Bluestone, Sonoma Biotherapeutics launched Thursday with a $40 million series A round to develop Treg-based cell therapies for autoimmune and neurodegenerative...
BioCentury | Dec 27, 2019
Product Development

Two-year-old Xyphos gains exit as Astellas scoops up CAR T switch platform

After splitting from parent company AvidBiotics in 2017, Xyphos has taken a short path to reward the decision with a takeout by Astellas. The Japanese pharma will use the technology to build its immuno-oncology pipeline,...
BC Innovations | Dec 6, 2019
Targets & Mechanisms

Emerging immuno-oncology mechanisms at ASH 2019

Researchers are finding new ways to monitor the immune system in hematologic diseases that could have implications for optimizing immuno-oncology therapies, according to BioCentury’s analysis of emerging targets at ASH 2019. In abstracts released ahead...
BC Innovations | Nov 1, 2019
Tools & Techniques

Draper’s devices take on cell therapy’s pain points

Having surveyed more than 60 cell therapy developers on what keeps them up at night, The Charles Stark Draper Laboratory Inc. is building a suite of microfluidic and acoustic tools to overcome the inefficiencies that...
BioCentury | Nov 1, 2019
Emerging Company Profile

Tmunity: Manufacturing momentum for CAR and TCR therapies

Tmunity’s $75 million series B round will enable the company to keep advancing its CMC capabilities alongside its clinical and preclinical engineered CAR and TCR therapies for solid and blood tumors. Andreessen Horowitz (a16z) led...
BioCentury | Oct 17, 2019
Emerging Company Profile

Parker Institute’s ArsenalBio launches with $85M to build cell engineering war chest

ArsenalBio launched Thursday with $85 million in a series A round to combine the technologies of its six Parker Institute co-founders into a suite of tools the company thinks could overcome key hurdles to cell...
BC Extra | Sep 19, 2019
Preclinical News

Sept. 19 Preclinical Quick Takes: Celsius' single-cell analysis; plus Merck's RSV therapy, glial cell transplant and methylation profiles for tumors

Celsius gets three single-cell analysis partners  Through separate deals, Celsius Therapeutics Inc. partnered with the Parker Institute for Cancer Immunotherapy, Institut Gustave-Roussy and University Health Network to apply its single-cell genomics platform, which includes machine-learning...
BC Innovations | May 30, 2019
Product Development

CAR T developers plan steps to reach more indications

As CAR T developers take stock after the first wave of approvals, they are drawing a to-do list of what changes are needed to broaden the modality from its narrow indications and fully exploit its...
Items per page:
1 - 10 of 49